EPF feedback on the implementing act on joint clinical assessments of medicinal products

The European Patients' Forum (EPF) welcomes the publication of the draft Implementing Act on Joint Clinical Assessments (JCA) of medicinal products, which sets out the rules for patient involvement in the context of JCA and brings us a step closer to implementing the EU HTA Regulation.

Incorporating patient perspectives into JCAs is essential as it provides evidence of patients' experiences of living with a disease, navigating treatments and assessing the potential impact on quality of life.

We commend the progress made in improving patient involvement, recognising the contribution of both individual patients and patient organisations. We also welcome the various ways in which patients can provide input, either during the assessment scope process or in the JCA and summary reports.

While progress has been made, patient involvement outlined in the Implementing Act must be further strengthened and refined to ensure predictability of involvement and representative and meaningful patient contributions.

Read our full statement here.